All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-07-04T10:12:50.000Z

What are the key considerations for CAR T-cell therapy in elderly patients with lymphoma?

By Camilla Rossi, Erika Roa
Featured
Anna Sureda
Jul 4, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma.

Bookmark this article

During the EHA 2022 Congress, the Lymphoma Hub spoke with Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What are the key considerations for CAR T-cell therapy in elderly patients with lymphoma?

What are the key considerations for CAR T-cell therapy in elderly patients with lymphoma?

Sureda outlines the phase III prospective randomized study ZUMA-7, which compared axicabtagene ciloleucel versus standard-of-care second-line therapy in adult patients with relapsed/refractory large B-cell lymphoma. Sureda discusses efficacy, safety, and toxicity results, highlighting that the primary endpoint was met.

 

More about...
CAR therapyEHA 2022Treatment of older patients with lymphoma and CLL

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Phase II study assesses the use of rituximab and bendamustine in frail, elderly DLBCL patients

The authors concluded that they found the combination of bendamustine and rituximab to be a good treatment option showing “promising activity” for elderly...

May 29, 2018
Add bookmark

Phase II study assesses the use of rituximab and bendamustine in frail, elderly DLBCL patients

The authors concluded that they found the combination of bendamustine and rituximab to be a good...

May 29, 2018
Add bookmark

Dr. Valentin Goede | EHA 2017 | Mantle Cell Lymphoma (MCL) in Elderly Patients

EHA 22nd Congress - June 22-25 2017, Madrid, Spain, Dr. Valentin Goede, University Hospital of Cologne, Cologne, Germany

Jun 25, 2017
Add bookmark

Dr. Valentin Goede | EHA 2017 | Mantle Cell Lymphoma (MCL) in Elderly Patients

EHA 22nd Congress - June 22-25 2017, Madrid, Spain, Dr. Valentin Goede, University Hospital of Cologne, Cologne, Germany

Jun 25, 2017

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox